Clinical TrialJun 11, 2026, 07:16 AM
Climb Bio's Budoprutug Phase 1b ITP Study Shows Positive Initial Data
AI Summary
Climb Bio, Inc. announced positive initial data from the Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP). The drug was generally well tolerated at 250 mg and 500 mg doses, with no serious adverse events or treatment discontinuations. Efficacy data from the 250 mg cohort showed significant B-cell depletion and increased platelet counts, with durable responses in a majority of patients, including those previously treated with rituximab.
Key Highlights
- Budoprutug was generally well tolerated at 250 mg and 500 mg doses with no serious adverse events.
- No treatment discontinuations due to adverse events or infusion related reactions were reported.
- In the 250 mg cohort, B-cell levels were depleted by over 90% by Week 4.
- Mean platelet count increased by 111,000 platelets/µL at Week 24 in the 250 mg cohort.
- Durable platelet responses were achieved in 4 out of 6 patients in the 250 mg dose cohort.
- Two out of six patients experienced platelet levels ≥100 x 10^3/µL for over 24 weeks.
- Three of four rituximab-pretreated patients responded to budoprutug, two with durable and complete responses.
- Enrollment in the 1000 mg cohort is ongoing, with additional data expected by year-end 2026.
Price Impact
More from CLYM